COLO B Coloplast A/S Class B

Coloplast A/S CEO Kristian Villumsen steps down as of today

Coloplast A/S CEO Kristian Villumsen steps down as of today

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO.

As the company is entering into a new strategy period, the Board of Directors has decided to initiate the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. As a result, President and CEO, Kristian Villumsen, steps down as of today.

To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as interim CEO. Accordingly, Lars Rasmussen steps down as Chair and will serve as an ordinary member of the Board. Board member Jette Nygaard-Andersen has been appointed interim Chair for the duration of Lars Rasmussens tenure as interim CEO.

Chair of the Board of Directors, Lars Rasmussen: "On behalf of the Board, I want to thank Kristian for his dedication and contributions to Coloplast over the past 17 years. Since becoming CEO in 2018, he has been instrumental in strengthening our market position, including through key strategic acquisitions. As we prepare to update our strategy, the Board believes it is time to bring in a new CEO to unfold the potential and drive long-term growth and value creation for the Coloplast group. I look forward to working with the executive leadership team while the Board conducts the search for Coloplast’s next CEO."

CEO Kristian Villumsen: "Over the past five years, we have made significant acquisitions and expanded into new high-growth segments, strengthening Coloplast’s foundation for growth. I am proud of what we have achieved together and wish the team every success going forward."

The new CEO of Coloplast is expected to be in place within the next 12 months, during which Lars Rasmussen will work closely with the executive leadership team to ensure continuity and accelerate momentum. He brings deep knowledge of Coloplast, having served as President & CEO from 2008 to 2018 and as part of executive management since 2001.

Jette Nygaard-Andersen has been a member of the Board of Directors since 2015 and serves on the Remuneration and Nomination Committee. She is considered independent and brings significant executive and board experience from global med-tech, including M&A activities and post-merger integration.

During his tenure as interim CEO and ordinary Board member, Lars Rasmussen will step down as Chair of the Remuneration and Nomination Committee and as a member of the Audit Committee. Jette Nygaard-Andersen will assume these responsibilities during this period.

Publication of H1 2024/25 Interim Report

Coloplast will release its H1 2024/25 Interim Report on 6 May 2025 and will host a conference call on the same day at 11h CEST, joined by interim CEO Lars Rasmussen and CFO Anders Lonning-Skovgaard.

 

Contacts

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Vice President, Investor Relations



Simone Dyrby Helvind

Senior Manager, Investor Relations

Tel. /

Press and media:

Jakob Danving Nielsen

Sr. Communications Manager



 

Attachment



EN
05/05/2025

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast annoncerer ændringer i ledelsesteamet

Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...

December 18, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast announces changes to Executive Leadership Team

Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...

December 18, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...

December 4, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Decisions at the Annual General Meeting 2025

Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...

December 4, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025

Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025 Indkaldelse til ordinær generalforsamling 2025 Den ordinære generalforsamling i Coloplast A/S afholdes torsdag den 4. december 2025 kl. 15:30 på Coloplast A/S’ adresse, Holtedam 3 (Aage Louis-Hansen Auditorium), Humlebæk, Danmark. Indkaldelsen til den ordinære generalforsamling er vedlagt.     For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardExecutive Vice President, CFOTlf. 4911 1111 Kristine Husted MunkSr. Director, Investor RelationsTlf. 4911 1800 / 4911 3266Email: Simo...

November 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch